IBT specializes in delivering top-notch reagents tailored for research and development purposes.
An animal model is a non-human species used in biomedical research because it can mimic aspects of a biological process or disease found in humans.
Disease-to-target discovery is the process of identification and early validation of targets involved in a disease.
The Plaque Reduction Neutralization Test (PRNT), often referred to as a PRNT assay, is used to measure the ability of antibodies or serum to neutralize a virus. It is a highly specific and quantitative method for determining the presence and potency of neutralizing antibodies in serum or other biological samples. The PRNT assay is commonly employed in virology research, vaccine development, and seroepidemiology.
Test articles (TAs) 1-4 are small molecule inhibitors tested against
DENV-2 Y98P in Vero cells in a PRNT assay. Dilutions of test articles were incubated with a known amount of virus and both test article dilutions and virus were added to cells for a set period of time before the addition of a methylcellulose layer. After a predetermined amount of time, plaques were counted and compared to the virus only control to calculate PRNT50 values.
All TAs show neutralizing activity against DENV-2 Y98P with TA2 exhibiting the most neutralization of D2 Y98P. The IBT internal control is a mouse monoclonal antibody against the Dengue envelope protein.
Antiserum was tested in a PRNT assay against ZIKV FSS13025. The antiserum was serially diluted for 12 dilutions and was incubated with ZIKV FSS13025 at a predetermined MOI. The antiserum and virus mixture was added to Vero cells in duplicate and a methylcellulose layer was later added. The cells were incubated for several days and then stained with crystal violet to visualize the ZIKV FSS13025 plaques. The lack of plaques in the first dilution indicates that the control is neutralizing toward ZIKV as no infection is observed.
The PRNT assay is based on the principle that neutralizing antibodies, present in a test serum, have the capacity to neutralize the infectivity of a virus by preventing it from infecting host cells. The test measures the dilution of serum at which 50% of the virus is neutralized, known as the 50% neutralization titer (PRNT50).
With years of experience in the field, our team of skilled scientists and technicians are well-versed in conducting PRNT assays for a wide range of pathogens, including influenza viruses, dengue viruses, Respiratory Syncytial Virus (RSV), and Herpes Simplex Virus (Plaque Reduction Neutralization Test ). We utilize state-of-the-art equipment and follow stringent quality control measures to ensure precise and reproducible results.
The PRNT assay is instrumental in assessing the ability of vaccines to induce neutralizing antibodies in individuals.
It is widely used in the study of the immune response to viral infections, the evaluation of antiviral treatments, and understanding the mechanisms of viral neutralization.
Some PRNT assays are used for diagnostic purposes to confirm the presence of neutralizing antibodies to specific viruses, especially in the context of certain viral diseases.
Our team of scientists and technicians are highly skilled and experienced in conducting HAI assays, ensuring accurate and reliable results.
We understand the unique needs of each research project and provide customized assay designs to meet your specific requirements.
We prioritize efficiency without compromising on quality. Our streamlined processes and advanced equipment allow for quick turnaround times, ensuring you receive results promptly.
We maintain rigorous quality control measures throughout our operations, ensuring the accuracy and reproducibility of our assay results.
Our dedicated customer support team is always available to address your queries and provide assistance at every step of the process.